Effects of Fumidil B on the spore of Nosema apis and on lipids of the host cell as revealed by freeze-etching

Myxozoan fish diseases: possible treatment and zoonoses

Myxozoan parasites pose huge threat to wild and cultured fishes and reported to cause heavy mortality, retarded growth and post-harvest quality degradation. It is one of the highly divergent groups of parasites which infects skin, gill, muscle, cartilage and internal organs of host fish and the severity of pathology varies depending on the water temperature, species of fish, site of tissue infection and immune resistance of the individual host. Most infections are difficult to treat, as they can easily evade host cellular and humoral defence mechanisms by proliferating or migrating through immune compromised sites of the host and forming large plasmodia encapsulated by the host cellular elements. This spore-forming parasite is harmless to humans but often detected in faecal samples of immunosuppressed humans. The incidences are mostly associated with the consumption of infected fish having a high concentration of spores which causes diarrhea and stomach pain. Currently, there are no immunostimulants or vaccines available for controlling these parasites, however, fumagillin is the drug of choice in fish for controlling this parasitic infection. Excessive usage of fumagillin causes tissue damage and retarded growth in fish, hence feed incorporation of this antibiotic in proper dose is essential for effective treatment. In this review detailed information on the diseases caused by myxozoan parasites in fishes and their zoonotic potential is discussed.

Therapeutic targets for the treatment of microsporidiosis in humans

INTRODUCTION

Microsporidia have been increasingly reported to infect humans. The most common presentation of microsporidiosis is chronic diarrhea, a significant mortality risk in immune-compromised patients. Albendazole, which inhibits tubulin, and fumagillin, which inhibits methionine aminopeptidase type 2 (MetAP2), are the two main therapeutic agents used for treatment of microsporidiosis. In addition, to their role as emerging pathogens in humans, microsporidia are important pathogens in insects, aquaculture, and veterinary medicine. New therapeutic targets and therapies have become a recent focus of attention for medicine, veterinary, and agricultural use. Areas covered: Herein, we discuss the detection and symptoms of microsporidiosis in humans and the therapeutic targets that have been utilized for the design of new drugs for the treatment of this infection, including triosephosphate isomerase, tubulin, MetAP2, topoisomerase IV, chitin synthases, and polyamines. Expert opinion: Enterocytozoon bieneusi is the most common microsporidia in human infection. Fumagillin has a broader anti-microsporidian activity than albendazole and is active against both Ent. bieneusi and Encephaliozoonidae. Microsporidia lack methionine aminopeptidase type 1 and are, therefore, dependent on MetAP2, while mammalian cells have both enzymes. Thus, MetAP2 is an essential enzyme in microsporidia and new inhibitors of this pathway have significant promise as therapeutic agents.

Ultrastructural changes in the secretion granules of the hypopharyngeal glands of the honeybee infected by Nosema apis and after treatment with fumagillin

Electron-dense secretion granules were numerous in the hypopharyngeal glands of healthy honeybees. In the hyopharyngeal glands of honeybees infected by Nosema apis, these granules appeared to have increased in size and lost their electron density, possessing a core area that consisted of numerous smaller granules, and a slightly electron dense fringe area, which in some cases possessed a crystalline structure. In the hypopharyngeal glands of infected honeybees after treatment with fumagillin, the secretion granules were also large and slightly electron dense, but the granular content was homogenous. Some of these granules were also partially crystallized. These ultrastructural changes in the secretion granules of diseased and fumagillin treated bees, is probably associated with a change in secretory activity of the glands.

Microsporidia and the society for invertebrate pathology: A personal point of view

In this overview, I trace the history of the study of microsporidia, with special emphasis on the collegial relationships that developed at the international level and were fostered by the establishment of the Society for Insect Pathology, which later became the Society for Invertebrate Pathology. Study of these organisms of invertebrates in the early days seemed to be mere curiosities, but it soon became clear that they were major disease-causing agents in insects, and later even in vertebrates, especially humans with compromised immune systems. Though microsporidia have not proven effective as pesticides, they do play a role in the regulation of insect populations, especially insects such as the gypsy moth, grasshoppers, and occasionally mosquitoes.

Drug treatment of microsporidiosis

Microsporidia are ubiquitous organisms that are emerging pathogens in humans. These are most likely zoonotic and/or waterborne infections. In the immunosuppressed host, such as those treated with immunosuppressive drugs or infected with human immunodeficiency virus particularly at advanced stages of the disease, microsporidia can produce a wide range of clinical diseases. The most common manifestation is gastrointestinal tract infection; however, encephalitis, ocular infection, sinusitis, myositis and disseminated infection have also been described. In addition, these organisms have been reported in immune competent individuals. Multiple genera are involved in these infections and different organisms can result in distinct clinical pictures. Differences in clinical and parasitologic response to various therapeutic agents have emerged from clinical, as well as in vitro and in vivo studies. Currently there are no precisely defined guidelines for the optimal treatment of microsporidial infections. This article reviews the available data on compounds with in vitro activity and/or in vivo efficacy for microsporidial infections. Copyright 2000 Harcourt Publishers Ltd.

Sporozoites of mammalian malaria: attachment to, interiorization and fate within macrophages

Sporozoites of Plasmodium berghei and Plasmodium knowlesi, incubated in normal serum readily interact with peritoneal macrophages of mice or rhesus monkeys, respectively. Interiorization of the sporozoite requires that both serum and macrophages be obtained from an animal susceptible to infection by the malaria parasite. Serum requirements for sporozoite attachment to the macrophage are less specific. Phagocytosis is not essential for the parasites to become intracellular. Our findings indicate that active penetration of the sporozites into the macrohages does occur. Antibodies present in the serum of sporozoite-immunized mice are important in determining the fate of both the intracellular sporozoites and the macrophages containing the parasite. Sporozoites coated with antibodies degenerate within vacuoles of the macrophages, which have no morphologic alteration. Sporozoites incubated in normal serum do not degenerate within macrophages, but the parasitized macrophages become morphologically altered and are destroyed. Preliminary experiments indicate that sporozoites appear to interact with rat Kupffer cells in the same way as with the peritoneal mouse macrophages. It is postulated that Kupffer cells play a dual role in sporozoite-host cell interaction. In normal animals these cells might serve to localize the sporozoites in the immediate vicinity of the hepatocytes. In the immunized animals, macrophages would remove and destroy the antibody-coated parasites, thus contributing to sporozoite-induced resistance.